4 Reasons Pfizer Could Be a Value Play You Can't Miss BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to ...

In an effort to reallocate resources to its growing oncology focus in the face of shrinking COVID-19 vaccine sales, German ...

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. BioNTech will ...

German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer ...

BioNTech has already been tinkering with its manufacturing processes in the run up to CAR-T BNT211 entering pivotal trials. Now, the German biotech has brought British company Autolus Therapeutics on ...

SINGAPORE – German biotechnology firm BioNTech, which has suffered large revenue declines in recent quarters, will shut its vaccine and therapeutic drug manufacturing plant in Singapore by February ...

On 25 July 2022, BioNTech SE and BioNTech Manufacturing GmbH (collectively, BioNTech) and Pfizer Inc. (Pfizer) (collectively, Plaintiffs) filed suit 1 in the District of Massachusetts against CureVac ...

MAINZ, Germany, February 2, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced construction completion of the Company’s first proprietary plasmid DNA manufacturing facility ...